MedTrace Logo

Study of HS-10384 in Participants of Chinese Postmenopausal Women

NCT06122181 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-03-13

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled phase Ib clinical study to evaluate the safety, tolerability and pharmacokinetics characteristics of HS-10384 in Chinese postmenopausal women.

Conditions

Interventions

DRUG

HS-10384 tablets

Multiple dosing of HS-10384 orally in a fasting state

DRUG

HS-10384-matched placebo tablets

Multiple dosing of HS-10384-matched placebo orally in a fasting state

Sponsors & Collaborators

  • Hansoh BioMedical R&D Company

    lead INDUSTRY

Principal Investigators

  • Rong Li, PhD · Peking University Third Hospital

  • Dongyang Liu · Peking University Third Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-12
Primary Completion
2024-06-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06122181 on ClinicalTrials.gov